Scholarlink

<p>Sphingosine kinase 1 (SPHK1) is an important enzyme involved in sphingolipid metabolism and has been linked to tumor progression in various cancers. However, its clinical significance in papillary thyroid carcinoma (PTC) remains uncertain. We examined SPHK1 expression using immunohistochemistry on tissue microarrays from 471 patients diagnosed with PTC, with expression levels quantified using the H-score method. SPHK1 positivity, defined as an H-score ≥ 10, was observed in 85 cases (18.0%) and was significantly associated with the <i>BRAF</i> p.V600E mutation (<i>p</i> &lt; 0.001) but not with tumor size, extrathyroidal extension, or lymph node metastasis. In patients younger than 55 years, SPHK1 positivity was associated with improved recurrence-free survival (RFS) (<i>p</i> = 0.046), and this prognostic benefit remained significant in the subgroup receiving radioactive iodine therapy (<i>p</i> = 0.028). Multivariate Cox regression analysis confirmed SPHK1 positivity as an independent predictor of favorable RFS (<i>p</i> = 0.036). Unlike its recognized oncogenic role in other malignancies, SPHK1 may function as a context-dependent biomarker in PTC, particularly among younger patients treated with radioactive iodine, possibly reflecting enhanced immune surveillance or altered tumor–microenvironment interactions. Further investigations are warranted to clarify the immunomodulatory and therapeutic implications of SPHK1 in differentiated thyroid cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Positive prognostic implications of SPHK1 expression in patients with papillary thyroid carcinoma undergoing radioactive iodine therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月13日

查看全文
  • Kyung Won Park,
  • Ja Seong Bae,
  • Dong-Jun Lim,
  • Chan Kwon Jung

摘要

Sphingosine kinase 1 (SPHK1) is an important enzyme involved in sphingolipid metabolism and has been linked to tumor progression in various cancers. However, its clinical significance in papillary thyroid carcinoma (PTC) remains uncertain. We examined SPHK1 expression using immunohistochemistry on tissue microarrays from 471 patients diagnosed with PTC, with expression levels quantified using the H-score method. SPHK1 positivity, defined as an H-score ≥ 10, was observed in 85 cases (18.0%) and was significantly associated with the BRAF p.V600E mutation (p < 0.001) but not with tumor size, extrathyroidal extension, or lymph node metastasis. In patients younger than 55 years, SPHK1 positivity was associated with improved recurrence-free survival (RFS) (p = 0.046), and this prognostic benefit remained significant in the subgroup receiving radioactive iodine therapy (p = 0.028). Multivariate Cox regression analysis confirmed SPHK1 positivity as an independent predictor of favorable RFS (p = 0.036). Unlike its recognized oncogenic role in other malignancies, SPHK1 may function as a context-dependent biomarker in PTC, particularly among younger patients treated with radioactive iodine, possibly reflecting enhanced immune surveillance or altered tumor–microenvironment interactions. Further investigations are warranted to clarify the immunomodulatory and therapeutic implications of SPHK1 in differentiated thyroid cancer.